ReviewDrugs2016
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.Human vaccines & immunotherapeutics · 2019Trial
- Assessing dengue knowledge, attitudes and preventive practices in France and Italy: A cross-sectional study using participatory surveillance cohorts.PLOS global public health · 2026Article
- Epidemiological Trends and Age-Period-Cohort Effects on Dengue Incidence Across High-Risk Regions from 1992 to 2021.Tropical medicine and infectious disease · 2025Article
- Molecular epidemiology and evolutionary characteristics of dengue virus 2 in East Africa.Nature communications · 2024Article
- Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement.Journal of biomedical science · 2023Article
- Developing a Vaccine to Block West Nile Virus Transmission: In Silico Studies, Molecular Characterization, Expression, and Blocking Activity ofPathogens (Basel, Switzerland) · 2021Article
- A Review:Vaccines · 2021Review
- A fluorescence-activatable reporter of flavivirus NS2B-NS3 protease activity enables live imaging of infection in single cells and viral plaques.The Journal of biological chemistry · 2020Article
- Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection.Antimicrobial agents and chemotherapy · 2019Article
- Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti.PLoS neglected tropical diseases · 2019Article
- Article
- The Conserved Molecular Determinants of Virulence in Dengue Virus.International journal of medical sciences · 2019Review
- Biochemical Effects ofInsects · 2018Article
- Dengue Virus Infection of Primary Human Smooth Muscle Cells.The American journal of tropical medicine and hygiene · 2018Article
- Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone.Emerging microbes & infections · 2018Article
- Limiting global-mean temperature increase to 1.5-2 °C could reduce the incidence and spatial spread of dengue fever in Latin America.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Towards the Application of Human Defensins as Antivirals.Biomolecules & therapeutics · 2018Review
- NS3 helicase from dengue virus specifically recognizes viral RNA sequence to ensure optimal replication.Nucleic acids research · 2017Article
- Human macrophages differentiated in the presence of vitamin D3 restrict dengue virus infection and innate responses by downregulating mannose receptor expression.PLoS neglected tropical diseases · 2017Article
- A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tetravalent, live-attenuated, dengue vaccine (Dengvaxia(®); CYD-TDV) is the first vaccine approved for the prevention of dengue disease caused by dengue virus (DENV) serotypes 1-4 in individuals aged 9-45 or 9-60 years living in high dengue endemic areas. This narrative review discusses the immunogenicity, protective efficacy, reactogenicity and safety of CYD-TDV in the prevention of dengue disease. In Latin American and Asian phase 3 trials in children and adolescents (n > 30,000), the recommended three-dose CYD-TDV regimen was efficacious in preventing virologically-confirmed dengue (VCD) during the period from 28 days after the last dose (month 13) to month 25, meeting the primary endpoint criteria. Protective efficacy against VCD in the respective individual trials was 60.8 and 56.5 % (primary analysis). During the 25-month active surveillance phase, CYD-TDV also provided protective efficacy against VCD, severe dengue, any grade of dengue haemorrhagic fever and VCD-related hospitalization in children aged 9 years and older. CYD-TDV was generally well tolerated, with no safety concerns identified after up to 4 years' follow-up (i.e. from post dose 1) in ongoing long-term studies. Based on evidence from the dengue clinical trial program, the WHO SAGE recommended that countries with high dengue endemicity consider introducing CYD-TDV as part of an integrated disease prevention strategy to lower disease burden. Pharmacoeconomic considerations will be pivotal to implementing dengue vaccination prevention strategies in these countries. The availability of a dengue vaccine is considered essential if the 2012 WHO global strategy targets for reducing the burden of dengue disease by 2020 are to be attained. Hence, CYD-TDV represents a major advance for the prevention of dengue disease in high dengue endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.